Protara Therapeutics/$TARA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Protara Therapeutics
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Ticker
$TARA
Sector
Primary listing
Employees
46
Headquarters
Website
TARA Metrics
BasicAdvanced
$285M
-
-$1.34
1.44
-
Price and volume
Market cap
$285M
Beta
1.44
52-week high
$7.82
52-week low
$2.77
Average daily volume
1.1M
Financial strength
Current ratio
14.581
Quick ratio
14.335
Long term debt to equity
1.078
Total debt to equity
1.71
Profitability
EBITDA (TTM)
-64.187
Management effectiveness
Return on assets (TTM)
-20.64%
Return on equity (TTM)
-31.60%
Valuation
Price to book
1.44
Price to tangible book (TTM)
1.44
Price to free cash flow (TTM)
-3.998
Free cash flow yield (TTM)
-25.01%
Free cash flow per share (TTM)
-1.318
Growth
Earnings per share change (TTM)
-38.08%
3-year earnings per share growth (CAGR)
-38.83%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Protara Therapeutics stock?
Protara Therapeutics (TARA) has a market cap of $285M as of March 20, 2026.
What is the P/E ratio for Protara Therapeutics stock?
The price to earnings (P/E) ratio for Protara Therapeutics (TARA) stock is 0 as of March 20, 2026.
Does Protara Therapeutics stock pay dividends?
No, Protara Therapeutics (TARA) stock does not pay dividends to its shareholders as of March 20, 2026.
When is the next Protara Therapeutics dividend payment date?
Protara Therapeutics (TARA) stock does not pay dividends to its shareholders.
What is the beta indicator for Protara Therapeutics?
Protara Therapeutics (TARA) has a beta rating of 1.44. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.